Dr. Willmar Schwabe GmbH & Co. KG

5 trials 1 recruiting Commercial sponsor

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

3 Completed trials

5 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I (Other)

Other

Phase III: 1 Phase II: 1 Phase IV: 1 Phase I (Other): 1 Other: 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cognitive disorder 1 Post-acute COVID-19 syndrome 1 Major depression 1 Functional gastrointestinal disorder 1

Top IMPs

LAVENDER OIL 1 PEPPERMINT OIL, CARAWAY OIL 1 REFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED TO 22.0 TO 27.0 % OF FLAVONOIDS EXPRESSED AS FLAVONE GLYCOSIDES, 2.8 TO 3.4 % OF GINKGOLIDES A, B AND C, AND 2.6 TO 3.2 % OF BILOBALIDE. EXTRACTION SOLVENT: ACETONE 60% (M/M) 1

All trials

5 total

A randomized, open-label, two-period, two-sequence crossover trial to investigate the effect of food on the pharmacokinetics of Silexan 80 m… Pending

2024-514373-22-00 Phase I (Other) 1 country
Silexan® in mild to moderate major depressive disorder Recruiting

2025-521744-37-00 Phase III 2 countries LAVENDER OIL
A trial to find the effect of Ginkgo biloba extract EGb 761® and how safe it is in participants with cognitive impairment associated with po… Ended

2024-517199-39-00 Phase II 3 countries REFINED AND QUANTIFIED DRY EXTRACT OF GINKGO BILOBA LEAVES (35-67:1) QUANTIFIED …
A randomised, open-label, reference-replicated crossover trial to investigate the bioequivalence of two formulations of Silexan 80 mg in hea… Ended

2023-503647-34-00 1 country
Menthacarin® in the treatment of functional gastrointestinal disorders Ended

2022-501800-92-00 Phase IV 1 country PEPPERMINT OIL, CARAWAY OIL

Showing 1–5 of 5 trials

← All sponsors A–Z